北欧银屑病关节炎患者启用生物制剂时炎症标志物较轻:一项人群队列研究
结果显示一线生物制剂以原研TNF抑制剂为主,2015至2017年生物类似药快速增加,且患者启用生物制剂时的疾病活动度逐年降低。
要点
- 北欧银屑病关节炎患者启用生物制剂的数量从2006至2017年增加。
- 2015至2017年生物类似药使用快速增加。
- 患者启用生物制剂时的疾病活动度较往年降低。
核心结论
- 北欧国家银屑病关节炎患者处方生物制剂的数量从2006至2017年增加,提示既往存在未被满足的生物制剂需求。
- 近年银屑病关节炎患者启用生物制剂时疾病活动度较往年降低,提示生物制剂用于炎症表型较轻的患者。
主要发现
- 全部患者中54%为女性。
- 一线生物制剂DMARD中原研TNF抑制剂占34.3%,certolizumab pegol和golimumab占8%,生物类似药占7.5%,ustekinumab占0.3%。
- 后续生物制剂DMARD中原研TNF抑制剂占25.2%,certolizumab pegol和golimumab占9%,生物类似药占12%,ustekinumab占2.1%。
- 2015至2017年生物类似药使用快速增加。
- 2006至2017年一线生物制剂启用者中低疾病活动度患者增加,R2接近1显示强关联。
临床怎么用
- 北欧数据显示银屑病关节炎生物制剂治疗率上升,且启用时疾病活动度降低,提示治疗时机可能提前。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess secular trends in baseline characteristics of PsA patients initiating their first or subsequent biologic DMARD (bDMARD) therapy and to explore prescription patterns and treatment rates of bDMARDs from 2006 to 2017 in the Nordic countries. METHODS: PsA patients registered in the Nordic rheumatology registries initiating any treatment with bDMARDs were identified. The bDMARDs were grouped as original TNF inhibitor [TNFi; adalimumab (ADA), etanercept (ETN) and infliximab (IFX)]; certolizumab pegol (CZP) and golimumab (GOL); biosimilars and ustekinumab, based on the date of release. Baseline characteristics were compared for the five countries, supplemented by secular trends with R2 calculations and point prevalence of bDMARD treatment. RESULTS: A total of 18 089 patients were identified (Denmark, 4361; Iceland, 449; Norway, 1948; Finland, 1069; Sweden, 10 262). A total of 54% of the patients were female, 34.3% of patients initiated an original TNFi, 8% CZP and GOL, 7.5% biosimilars and 0.3% ustekinumab as a first-line bDMARD. Subsequent bDMARDs were 25.2% original TNFi, 9% CZP and GOL, 12% biosimilars and 2.1% ustekinumab. From 2015 through 2017 there was a rapid uptake of biosimilars. The total of first-line bDMARD initiators with lower disease activity increased from 2006 to 2017, where an R2 close to 1 showed a strong association. CONCLUSION: Across the Nordic countries, the number of prescribed bDMARDs increased from 2006 to 2017, indicating a previously unmet need for bDMARDs in the PsA population. In recent years, PsA patients have initiated bDMARDs with lower disease activity compared with previous years, suggesting that bDMARDs are initiated in patients with a less active inflammatory phenotype.
引用
- Lund Hansen R, Schoedt Jørgensen T, Dreyer L, et al. Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: a Nordic population-based cohort study. Rheumatology (Oxford). 2021. PMID: 32591790. doi:10.1093/rheumatology/keaa237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。